The hepatitis A virus causes disease of the liver and is spread by eating contaminated food or from person to person. While the symptoms are generally mild, they can become more severe and last up to 6 months.
What are the symptoms?
Symptoms usually develop 28 days (but range from 15 to 50 days) after catching the virus – although many people infected with hepatitis A, especially children, show few or no symptoms.
If there are symptoms, they can be mild lasting only a week or two; or severe lasting up to six months. They can include:
- fever
- tiredness
- loss of appetite
- nausea
- vomiting
- abdominal pain
- dark urine
- clay-coloured stools
- joint pain
- jaundice (yellowing of eyes and/or skin).
Most people fully recover from hepatitis A.
This is not a full list of symptoms that can occur following hepatitis A infection. Please speak to a healthcare professional if you have any concerns about hepatitis A.
How is it spread?
The hepatitis A virus can survive outside the body, living on hands for several hours and even longer in food stored at room temperature.
The virus is found in the faeces of an infected person – it generally spreads to others if food or water becomes contaminated with their faeces. It can also be spread by direct person-to-person contact.
Who is at risk?
Aboriginal and Torres Strait Islander children are at greater risk of infection and hospitalisation than non- Aboriginal and Torres Strait Islander children.
You may have higher risk of infection if:
- you travel to areas where hepatitis A is common
- there is an occupational or lifestyle risk of exposure to hepatitis A
- you have a chronic liver condition.
- you have not been immunised
Other people may be at risk of hepatitis A infection. Please speak to a healthcare professional regarding your individual circumstances.
Discover tips to help strengthen immune system function and keep you feeling your best as you age. Talk to your doctor about ways to maintain a healthy immune system and embrace healthy ageing
PM-AU-AVX-WCNT-190034 Date of GSK Approval: January 2021